| Title |
Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels
|
|---|---|
| Published in |
Cellular and Molecular Life Sciences, May 2006
|
| DOI | 10.1007/s00018-006-6037-3 |
| Pubmed ID | |
| Authors |
M. van der Stelt, C. Mazzola, G. Esposito, I. Matias, S. Petrosino, D. De Filippis, V. Micale, L. Steardo, F. Drago, T. Iuvone, V. Di Marzo |
| Abstract |
We investigated the involvement of endocannabinoids in the control of neuronal damage and memory retention loss in rodents treated with the beta-amyloid peptide (1-42) (BAP). Twelve days after stereotaxic injection of BAP into the rat cortex, and concomitant with the appearance in the hippocampus of markers of neuronal damage, 2-arachidonoyl glycerol, but not anandamide, levels were enhanced in the hippocampus. VDM-11 (5 mg/kg, i.p.), an inhibitor of endocannabinoid cellular reuptake, significantly enhanced rat hippocampal and mouse brain endocannabinoid levels when administered sub-chronically starting either 3 or 7 days after BAP injection and until the 12-14th day. VDM-11 concomitantly reversed hippocampal damage in rats, and loss of memory retention in the passive avoidance test in mice, but only when administered from the 3rd day after BAP injection. We suggest that early, as opposed to late, pharmacological enhancement of brain endocannabinoid levels might protect against beta-amyloid neurotoxicity and its consequences. |
Mendeley readers
The data shown below were compiled from readership statistics for 143 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 2% |
| United Kingdom | 2 | 1% |
| Germany | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 136 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 25 | 17% |
| Researcher | 24 | 17% |
| Student > Master | 19 | 13% |
| Student > Bachelor | 16 | 11% |
| Student > Doctoral Student | 7 | 5% |
| Other | 21 | 15% |
| Unknown | 31 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 23 | 16% |
| Neuroscience | 20 | 14% |
| Medicine and Dentistry | 16 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 7% |
| Biochemistry, Genetics and Molecular Biology | 10 | 7% |
| Other | 20 | 14% |
| Unknown | 44 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2021.
All research outputs
#2,858,478
of 23,794,258 outputs
Outputs from Cellular and Molecular Life Sciences
#444
of 4,151 outputs
Outputs of similar age
#5,954
of 65,791 outputs
Outputs of similar age from Cellular and Molecular Life Sciences
#7
of 37 outputs
Altmetric has tracked 23,794,258 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,151 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 65,791 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.